Literature DB >> 24623134

Functional characterization of ocular-derived human alphaherpesvirus cross-reactive CD4 T cells.

Werner J D Ouwendijk1, Annemieke Geluk, Saskia L Smits, Sarah Getu, Albert D M E Osterhaus, Georges M G M Verjans.   

Abstract

Intraocular varicella-zoster virus (VZV) and HSV type 1 (HSV-1) infections cause sight-threatening uveitis. The disease is characterized by an intraocular inflammatory response involving herpesvirus-specific T cells. T cell reactivity to the noncausative human alphaherpesvirus (αHHV) is commonly detected in the affected eyes of herpetic uveitis patients, suggesting the role of cross-reactive T cells in the disease. This study aimed to identify and functionally characterize intraocular human alphaherpesvirus cross-reactive T cells. VZV protein immediate early 62 (IE62), which shares extensive homology with HSV ICP4, is a previously identified T cell target in VZV uveitis. Two VZV-specific CD4 T cell clones (TCC), recovered from the eye of a VZV uveitis patient, recognized the same IE62918-927 peptide using different TCR and HLA-DR alleles. The IE62918-927 peptide bound with high affinity to multiple HLA-DR alleles and was recognized by blood-derived T cells of 5 of 17 HSV-1/VZV-seropositive healthy adults but not in cord blood donors (n = 5). Despite complete conservation of the IE62 epitope in the orthologous protein ICP4 of HSV-1 and HSV-2, the TCC recognized VZV and HSV-1- but not HSV-2-infected B cells. This was not attributed to proximal epitope-flanking amino acid polymorphisms in HSV-2 ICP4. Notably, VZV/HSV-1 cross-reactive CD4 T cells controlled VZV but not HSV-1 infection of human primary retinal pigment epithelium (RPE) cells. In conclusion, we report on the first VZV/HSV-1 cross-reactive CD4 T cell epitope, which is HLA-DR promiscuous and immunoprevalent in coinfected individuals. Moreover, ocular-derived peptide-specific CD4 TCC controlled VZV but not HSV-1 infection of RPE cells, suggesting that HSV-1 actively inhibits CD4 T cell activation by infected human RPE cells.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24623134     DOI: 10.4049/jimmunol.1302307

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

1.  Subclinical Herpes Simplex Virus Type 1 Infections Provide Site-Specific Resistance to an Unrelated Pathogen.

Authors:  Alexander M Rowe; Hongming Yun; Benjamin R Treat; Paul R Kinchington; Robert L Hendricks
Journal:  J Immunol       Date:  2017-01-06       Impact factor: 5.422

2.  Phenotypic and functional characterization of herpes simplex virus glycoprotein B epitope-specific effector and memory CD8+ T cells from symptomatic and asymptomatic individuals with ocular herpes.

Authors:  Arif A Khan; Ruchi Srivastava; Doran Spencer; Sumit Garg; Daniel Fremgen; Hawa Vahed; Patricia P Lopes; Thanh T Pham; Charlie Hewett; Jasmine Kuang; Nicolas Ong; Lei Huang; Vanessa M Scarfone; Anthony B Nesburn; Steven L Wechsler; Lbachir BenMohamed
Journal:  J Virol       Date:  2015-01-21       Impact factor: 5.103

3.  A Randomized, Double-Blinded, Placebo-Controlled, Phase 1 Study of a Replication-Defective Herpes Simplex Virus (HSV) Type 2 Vaccine, HSV529, in Adults With or Without HSV Infection.

Authors:  Lesia K Dropulic; Makinna C Oestreich; Harlan L Pietz; Kerry J Laing; Sally Hunsberger; Keith Lumbard; Doreen Garabedian; Siu Ping Turk; Aiying Chen; Ronald L Hornung; Chetan Seshadri; Malisa T Smith; Nancy A Hosken; Sanjay Phogat; Lee-Jah Chang; David M Koelle; Kening Wang; Jeffrey I Cohen
Journal:  J Infect Dis       Date:  2019-08-09       Impact factor: 5.226

4.  Diversification of the antigen-specific T cell receptor repertoire after varicella zoster vaccination.

Authors:  Qian Qi; Mary M Cavanagh; Sabine Le Saux; Hong NamKoong; Chulwoo Kim; Emerson Turgano; Yi Liu; Chen Wang; Sally Mackey; Gary E Swan; Cornelia L Dekker; Richard A Olshen; Scott D Boyd; Cornelia M Weyand; Lu Tian; Jörg J Goronzy
Journal:  Sci Transl Med       Date:  2016-03-30       Impact factor: 17.956

5.  Phenotypic and Functional Signatures of Herpes Simplex Virus-Specific Effector Memory CD73+CD45RAhighCCR7lowCD8+ TEMRA and CD73+CD45RAlowCCR7lowCD8+ TEM Cells Are Associated with Asymptomatic Ocular Herpes.

Authors:  Ruchi Srivastava; Pierre-Grégoire Coulon; Soumyabrata Roy; Sravya Chilukuri; Sumit Garg; Lbachir BenMohamed
Journal:  J Immunol       Date:  2018-09-10       Impact factor: 5.422

6.  Zoster Vaccination Increases the Breadth of CD4+ T Cells Responsive to Varicella Zoster Virus.

Authors:  Kerry J Laing; Ronnie M Russell; Lichun Dong; D Scott Schmid; Michael Stern; Amalia Magaret; Jürgen G Haas; Christine Johnston; Anna Wald; David M Koelle
Journal:  J Infect Dis       Date:  2015-03-17       Impact factor: 5.226

7.  A spliced latency-associated VZV transcript maps antisense to the viral transactivator gene 61.

Authors:  Daniel P Depledge; Werner J D Ouwendijk; Tomohiko Sadaoka; Shirley E Braspenning; Yasuko Mori; Randall J Cohrs; Georges M G M Verjans; Judith Breuer
Journal:  Nat Commun       Date:  2018-03-21       Impact factor: 14.919

8.  Extensive CD4 and CD8 T Cell Cross-Reactivity between Alphaherpesviruses.

Authors:  Lichen Jing; Kerry J Laing; Lichun Dong; Ronnie M Russell; Russell S Barlow; Juergen G Haas; Meena S Ramchandani; Christine Johnston; Soren Buus; Alec J Redwood; Katie D White; Simon A Mallal; Elizabeth J Phillips; Christine M Posavad; Anna Wald; David M Koelle
Journal:  J Immunol       Date:  2016-01-25       Impact factor: 5.422

9.  Analysis of Virus and Host Proteomes During Productive HSV-1 and VZV Infection in Human Epithelial Cells.

Authors:  Werner J D Ouwendijk; Lennard J M Dekker; Henk-Jan van den Ham; Tihana Lenac Rovis; Erik S Haefner; Stipan Jonjic; Jürgen Haas; Theo M Luider; Georges M G M Verjans
Journal:  Front Microbiol       Date:  2020-05-29       Impact factor: 5.640

10.  Decoding the Architecture of the Varicella-Zoster Virus Transcriptome.

Authors:  Werner J D Ouwendijk; Daniel P Depledge; Shirley E Braspenning; Tomohiko Sadaoka; Judith Breuer; Georges M G M Verjans
Journal:  mBio       Date:  2020-10-06       Impact factor: 7.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.